Add Formweb to your mobile device
Search results for:
granisetron
granisetron
Brand names: Granisetron HYDROCHLORIDE, Granisetron HYDROCHLORIDE Preservative-Free
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, INTRAVENOUS | 1 mg/mL | Restricted to pediatrics who have failed ondansetron therapy. 1736 NOS | ||||||||||
| TABLET, ORAL | 1 mg | Restricted to pediatrics who have failed ondansetron therapy |
Last updated: May. 30, 2025
- Restricted: Restricted to pediatrics who have failed ondansetron therapy
Medications Approved for Automatic Therapeutic Interchange Dosage Conversion Guidelines
(Note: “Therapeutic Interchange” should be placed in the order comments.)
5-HT3 Antagonists
Medication
Ordered
Brand Name
Available Dosages
Frequency
Formulary Medication
Equivalent
Dose
Equivalent Frequency
Granisetron
Kytril
1 mg
Same as ordered
Ondansetron
16 mg
Same as ordered
2 mg
Dolasetron
Anzemet
100 mg
200 mg
*Palonosetron
Aloxi
250 mcg
Once
Ondansetron
16 mg*
Once, may repeat q4h PRN x2 more doses
Note: IV granisetron approved for use in pediatric patients who have failed ondansetron
Note: If the dosing falls outside of the above dosing, contact the MD to clarify conversion.
*OLOL P&T approval (April 2022): When ordered from an oncology treatment plan for inpatient administration, the automatic therapeutic interchange for palonosetron 250mcg is ondansetron 8mg once on day 1 and each subsequent day of chemotherapy (if not already on the treatment plan for that day).